- 15 hrs ago Designer Virgil Abloh, Famous For High-End Streetwear, Passes Away At 41 From Cancer
- 17 hrs ago Omicron Reportedly Has 30+ Mutations In Spike Protein Region, May Bypass Vaccines: AIIMS Chief Randeep Guleria
- 18 hrs ago Amazon Sale: Awesome Smart And Elegant Watches For Women With Up To 60% Off
- 18 hrs ago Planning To Bleach Your Hair? 8 Things To Look Out For And A Step-By-Step Guide
- Movies Antim Day 4 Box Office Collection: Salman Khan-Aayush Sharma's Film Passes Monday Test
- News Opposition likely to skip entire Winter Session
- Sports Lionel Messi wins historic seventh Ballon d'Or
- Finance Small Cap Company Stock To Watch Out After Dolly Khanna Ups Stake
- Education KVPY Aptitude Test 2021 Date Announced, Check KVPY Fellowship Exam Date And Other Details Here
- Technology Oppo Reno7, Reno7 Pro India Pricing Details Out; Reno7 SE Not Coming
- Travel Discovery’s Lost Essence S2: Cyrus Sahukar Explores The Hidden Gems Of India
- Automobiles Nissan To Launch 15 New Electric Vehicles By 2030
The government will take a final decision on vaccinating children and adolescents against coronavirus on the basis of overall scientific rationale as well as the supply situation of vaccines available for those below 18 years, Covid task force chief V K Paul said on Sunday.
Paul also cautioned that even though infections were coming down and the second wave was subsiding, it would not be fair to say that the worst was over since many countries had seen more than two waves.
Currently, three vaccines - Covishield, Covaxin and Sputnik V - being administered in the country are only for those above 18. Zydus Cadila's needle-free vaccine ZyCoV-D is set to become the first that will be available in India for those between 12 and 18. It has received emergency use authorisation (EUA).
"We do know several countries have introduced vaccination for adolescents and children. We will make a final decision based on the overall scientific rationale and the supply situation of the child-licenced vaccines," Paul said.
An expert panel of India's central drug authority has recommended granting EUA to Bharat Biotech's Covaxin for children and adolescents in the 2-18 age group with certain conditions.
According to Paul, Covaxin is part of the adult vaccination programme and how to provide the vaccine, if at all for children, has to be also examined.
"A pragmatic decision can be taken (only) by balancing the supply and the potential eligibility," he said.
Paul said: "The preparation for incorporation of Zydus Cadila's vaccine into the vaccination programme is proceeding well, training is already being held."